Atrial fibrillation and congestive heart failure (AF-CHF) study
- Conditions
- Atrial fibrillation, congestive heart failureCirculatory SystemHeart failure
- Registration Number
- ISRCTN84858671
- Lead Sponsor
- Montreal Heart Institute (Canada)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 1375
1. Symptomatic CHF (New York Heart Association [NYHA] class II - IV) at some time during the 6 months before randomisation (instead of '3 months')
2. Aged greater than or equal to 50 years old, either sex
3. Left ventricular ejection fraction less than or equal to 35%
4. History of significant atrial fibrillation
5. Patients must be eligible for long term treatment with either treatment strategy of AF
6. AF is known to be present and uninterrupted for greater than 12 months prior to randomisation
1. Reverse cause of AF such as acute pericarditis, pulmonary embolism, hyperthyroidism, alcohol intoxication
2. Unstable (pulmonary oedema, hypoperfusion) decompensated CHF
3. Antiarrhythmic drugs other than calcium channel blockers, beta-blockers or digoxin required for other arrhythmias or indications
4. Atrial fibrillation occurring and not persisting beyond 10 days after surgery or myocardial infarction
5. Second or third degree AV block, sinus pause greater than 3 seconds, resting heart rate less than 50 bpm without a permanent pacemaker
6. History of drug-induced or congenital long QT syndrome
7. Reversible causes of CHF such as severe aortic or mitral stenosis and tachycardia-induced cardiomyopathy
8. Prior AV nodal ablation or maze surgery
9. Probable cardiac transplantation in the next 6 months
10. Chronic renal failure requiring dialysis
11. Women of childbearing potential and not on a reliable method of birth control
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method